Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 196 participants.

Also called NCT06486363

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 196 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06486363
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06486363. Randomized; no masking; primary purpose treatment. Start 2024-08-01 (anticipated); primary completion 2026-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype
Condition
Intracranial Aneurysms
Condition
Antiplatelet Drugs
Intervention (Drug)
Aspirin combined with clopidogrel
Intervention (Drug)
Aspirin combined with half-dose ticagrelor
Lead sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (class: other)

Record details

Record id
cardio:ct-nct06486363
Content hash
d6400222290bf8499e612fe143f89cd1ed5aa1fa6419624e2f747a88f365ae1d